title: Pre-hospital detection of acute myocardial infarction with ultra-rapid human fatty acid-binding protein (H-FABP) immunoassay.
abstract: OBJECTIVE
  To evaluate the diagnostic performance of a portable semi-quantitative whole blood immunoassay measuring soluble human fatty acid-binding protein [H-FABP] (CardioDetect) for the pre-hospital detection of myocardial infarction (MI).
  
  
  RESULTS
  We enrolled prospectively 108 consecutive patients with acute ischemic type chest pain in whom the first medical care was delivered by a mobile intensive care unit (MICU). CTnI, myoglobin, CK-MB and CardioDetect were first assessed in the MICU before hospital admission using point-of-care assays and then cTnI was serially measured during the hospital stay. MI was defined as a positive cTnI in any sample over the first 24 h. The vast majority of the patients (77/108) were admitted <3 h of symptoms onset. Pre-hospital cTnI sample was normal in 96 patients (88.9%) of whom 43 had subsequent cTnI elevation. A positive H-FABP using the CardioDetect assay had a significantly better sensitivity than cTnI, myoglobin and CK-MB (87.3% vs 21.8%, 64.2% and 41.5%, respectively) to identify MI. The significant better sensitivity of the CardioDetect assay was also observed among patients who presented <3 h of symptom onset. The specificity of the CardioDetect assay was significantly better than that of myoglobin, irrespective of the time delay from symptom onset to measurement. In patients with normal pre-hospital cTnI and no ST-elevation (n=63), assessment based only on a positive H-FABP had 83.3% sensitivity, 93.3% specificity for the diagnosis of an evolving MI.
  
  
  CONCLUSIONS
  Early assessment of H-FABP in patients presenting with chest pain improves the diagnosis of ongoing MI.
authors.affiliation: SAMU, Pitié-Salpêtrière University Hospital, Paris, France.
authors.forename: Patrick
authors.initials: P
authors.lastname: Ecollan
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Collet
authors.forename: Guillaume
authors.initials: G
authors.lastname: Boon
authors.forename: Marie-Laure
authors.initials: ML
authors.lastname: Tanguy
authors.forename: Marie-Laurence
authors.initials: ML
authors.lastname: Fievet
authors.forename: Rosita
authors.initials: R
authors.lastname: Haas
authors.forename: Nicolas
authors.initials: N
authors.lastname: Bertho
authors.forename: Shidash
authors.initials: S
authors.lastname: Siami
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Hubert
authors.forename: Pierre
authors.initials: P
authors.lastname: Coriat
authors.forename: Gilles
authors.initials: G
authors.lastname: Montalescot
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D052279:Creatine Kinase, MB Form / Q000097:blood; D004632:Emergency Medical Services; D000074026:Fatty Acid Binding Protein 3; D050556:Fatty Acid-Binding Proteins / Q000097:blood*; D005260:Female; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000175:diagnosis*; D009211:Myoglobin / Q000097:blood; D019095:Point-of-Care Systems; D012680:Sensitivity and Specificity; D019210:Troponin I / Q000097:blood
chemical_list: C493408:FABP3 protein, human; D000074026:Fatty Acid Binding Protein 3; D050556:Fatty Acid-Binding Proteins; D009211:Myoglobin; D019210:Troponin I; D052279:Creatine Kinase, MB Form